## Linlin Yang

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/288139/linlin-yang-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 12                | 1,327                | 8                   | 15              |
|-------------------|----------------------|---------------------|-----------------|
| papers            | citations            | h-index             | g-index         |
| 15<br>ext. papers | 1,797 ext. citations | <b>14.2</b> avg, IF | 4.33<br>L-index |

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 12 | A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010409         | 7.6  | O         |
| 11 | Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>Nature Communications</i> , <b>2021</b> , 12, 2938 | 17.4 | 110       |
| 10 | Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. <i>Nature Communications</i> , <b>2021</b> , 12, 3309                 | 17.4 | 25        |
| 9  | Liposomal Clodronate-mediated Macrophage Depletion in the Zebrafish Model. <i>Bio-protocol</i> , <b>2021</b> , 11, e3951   | 0.9  | 1         |
| 8  | Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , <b>2021</b> , 371, 823-829                              | 33.3 | 157       |
| 7  | Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , <b>2020</b> , 369, 956-963                  | 33.3 | 906       |
| 6  | A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1009089            | 7.6  | 33        |
| 5  | Drainage of inflammatory macromolecules from the brain to periphery targets the liver for macrophage infiltration. <i>ELife</i> , <b>2020</b> , 9,                       | 8.9  | 6         |
| 4  | Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model <b>2020</b> ,  |      | 35        |
| 3  | A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody <b>2020</b> ,  |      | 2         |
| 2  | Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection <b>2020</b> ,  |      | 40        |
| 1  | An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 <b>2020</b> ,  |      | 11        |